Healthcare -
Biotechnology - NASDAQ - US
$ 26.125
-8.04 %
$ 499 M
Market Cap
-10.82
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Structure Therapeutics Inc.
| Net Income | -123 M |
| Depreciation & Amortization | 992 K |
| Capital Expenditures | -1.29 M |
| Stock-Based Compensation | 18.8 M |
| Change in Working Capital | 2.96 M |
| Others | -17.2 M |
| Free Cash Flow | -118 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (122.5) | (89.6) | (51.3) | 38 K | 15.9 K |
| Depreciation & Amortization | 1.0 | 0.3 | 0.3 | 72 | 20 K |
| Deferred Income Tax | 0 | 0 | 0 | 27 | 20 K |
| Stock Based Compensation | 18.8 | 8.2 | 2.5 | 1.5 | 0.6 |
| Other Operating Activities | (16.9) | (5.3) | (0.6) | 241 | 77 |
| Change in Working Capital | 3.0 | 7.0 | 3.0 | 4.06 K | 946 |
| Cash From Operations | (116.6) | (79.5) | (46.1) | 32.2 K | 14.3 K |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (1.3) | (2.2) | (0.2) | 1.21 K | 19 |
| Other Items | (357.6) | (266.2) | (62.0) | 19.1 K | 21.1 K |
| Cash From Investing Activities | (358.9) | (268.3) | (62.1) | 17.9 K | 21.1 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 6 K | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.7 | (20.8) | 29.0 | 0.1 | 25.8 |
| Cash From Financing Activities | 515.3 | 451.5 | 29.0 | 0.1 | 25.8 K |
| CHANGE IN CASH | |||||
| Net Change In Cash | 39.7 | 103.7 | (79.2) | 89 K | 9.59 K |
| FREE CASH FLOW | |||||
| Free Cash Flow | (117.9) | (81.7) | (46.3) | 33.4 K | 14.3 K |